Key Takeaways
- • Throne Science closed a $10 million Series A funding round led by Will Ventures, with participation from 12 additional investors including Emerson Collective, Workshop, and LEAD VC.
- • The company's core product is a discreet sensor that attaches to standard toilets and uses AI-powered analytics to track gut health, hydration status, and urinary function data passively with every flush.
- • Throne Science positions continuous at-home health monitoring as a screening tool for early detection of colorectal cancer and urinary tract cancers, representing a significant market opportunity in preventive diagnostics.
- • The funding validates investor interest in non-invasive, consumer-accessible health monitoring technologies that generate continuous biometric data through everyday activities.
Summary
The company has developed a smart toilet sensor system designed to passively collect health data without requiring active user engagement. A compact sensor adheres to any standard toilet and captures diagnostic information across three primary health dimensions: gastrointestinal function, hydration levels, and urinary tract parameters. Data collection occurs automatically with each flush and is processed through Throne Science's proprietary artificial intelligence application, which synthesizes raw measurements into continuous health patterns and actionable insights presented in accessible, non-clinical formats for end users.
The company's long-term strategic objective centers on establishing the first widely accessible, continuous at-home screening platform for early-stage detection of colorectal cancer and urinary tract malignancies. This positioning reflects growing institutional investment thesis around non-invasive, continuous health monitoring that operates within the consumer's existing daily behavior patterns, eliminating friction associated with traditional diagnostic workflows. The combination of passive data collection, AI-driven pattern recognition, and early cancer detection creates a compelling value proposition across consumer health, clinical diagnostics, and preventive medicine markets.
The funding round's investor composition—spanning venture specialists, impact-focused capital, and established strategic investors—signals confidence in both the product's technical viability and the market's readiness for toilet-based health analytics. This capital will likely fund product development, regulatory pathway advancement, clinical validation studies, and market expansion necessary to establish Throne Science as a foundational player in remote patient monitoring and cancer screening infrastructure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.